ATE304533T1 - Tetrahydrochinolinderivate als muscarinische agonisten - Google Patents
Tetrahydrochinolinderivate als muscarinische agonistenInfo
- Publication number
- ATE304533T1 ATE304533T1 AT02794441T AT02794441T ATE304533T1 AT E304533 T1 ATE304533 T1 AT E304533T1 AT 02794441 T AT02794441 T AT 02794441T AT 02794441 T AT02794441 T AT 02794441T AT E304533 T1 ATE304533 T1 AT E304533T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- muscarinic agonists
- methods
- muscarinic receptor
- tetrahydrochinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34472201P | 2001-12-28 | 2001-12-28 | |
| PCT/US2002/041617 WO2003057672A2 (en) | 2001-12-28 | 2002-12-23 | Tetrahydroquinoline analogues as muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304533T1 true ATE304533T1 (de) | 2005-09-15 |
Family
ID=23351729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02794441T ATE304533T1 (de) | 2001-12-28 | 2002-12-23 | Tetrahydrochinolinderivate als muscarinische agonisten |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7307075B2 (de) |
| EP (1) | EP1461318B9 (de) |
| JP (1) | JP4509565B2 (de) |
| KR (1) | KR100972614B1 (de) |
| CN (1) | CN100402032C (de) |
| AT (1) | ATE304533T1 (de) |
| AU (1) | AU2002359875B2 (de) |
| BR (1) | BR0215430A (de) |
| CA (1) | CA2470578C (de) |
| DE (1) | DE60206198T2 (de) |
| DK (1) | DK1461318T3 (de) |
| ES (1) | ES2251624T3 (de) |
| HK (1) | HK1074573A1 (de) |
| IL (2) | IL162616A0 (de) |
| MX (1) | MXPA04006281A (de) |
| NO (1) | NO327522B1 (de) |
| NZ (1) | NZ533566A (de) |
| RU (1) | RU2292346C2 (de) |
| WO (1) | WO2003057672A2 (de) |
| ZA (1) | ZA200405024B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| IL162616A0 (en) | 2001-12-28 | 2005-11-20 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US20050130961A1 (en) * | 2003-03-28 | 2005-06-16 | Davis Robert E. | Muscarinic M1 receptor agonists for pain management |
| EP2468743A1 (de) | 2005-06-24 | 2012-06-27 | Toyama Chemical Co., Ltd. | Bicyclischen Stickstoff enthaltende heterocyclische Verbindungen zur Verwendung als antibakterielle Mittel |
| EP1928437A2 (de) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenese mittels muscarinrezeptormodulation |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| GB0607949D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| EP2026813A2 (de) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5-ht-rezeptor-vermittelte neurogenese |
| EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| CN101522197B (zh) * | 2006-07-31 | 2013-12-11 | 詹森药业有限公司 | 尾加压素ⅱ受体拮抗剂 |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2326644B1 (de) | 2008-08-02 | 2012-02-22 | Janssen Pharmaceutica N.V. | Urotensin-ii-rezeptorantagonisten |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN104039321B (zh) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | 药物化合物 |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3324137A (en) * | 1964-05-08 | 1967-06-06 | Sterling Drug Inc | N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes |
| US3365457A (en) * | 1964-05-08 | 1968-01-23 | Sterling Drug Inc | N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives |
| JPS63290821A (ja) * | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| JP2886570B2 (ja) * | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| US5149815A (en) * | 1991-04-29 | 1992-09-22 | American Home Products Corporation | N-substituted-2-aminoquinolines |
| US5378698A (en) | 1991-10-21 | 1995-01-03 | Shionogi & Co., Ltd. | Benzothiazepine derivatives |
| US5457099A (en) * | 1992-07-02 | 1995-10-10 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| DE4228095A1 (de) | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| TW448161B (en) * | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
| CZ292379B6 (cs) * | 1995-09-29 | 2003-09-17 | Glaxo Wellcome Spa | Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| EP0934932A4 (de) * | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | Chinolinderivate und psychotropes mittel |
| US5919750A (en) * | 1997-07-24 | 1999-07-06 | Akzo Nobel Nv | Fabric softener composition |
| JP2002509918A (ja) * | 1998-03-31 | 2002-04-02 | アケイディア ファーマスーティカルズ インコーポレイテッド | ムスカリン性レセプタに活性を有する化合物 |
| IL137656A0 (en) * | 1998-03-31 | 2001-10-31 | Warner Lambert Co | Benzoxazinones/benzothiazinones as serine protease inhibitors |
| WO2001027104A1 (fr) * | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Derives d'imidazolidinone a substitution |
| BR0016953A (pt) * | 1999-12-30 | 2003-02-25 | Lundbeck & Co As H | Derivados de 4-fenil-1-piperazinila, -piperidinila e tetraidropiridila substituìdo por halogênio, composto, composição farmacêutica, uso e método de tratamento |
| CN100384836C (zh) * | 2000-02-29 | 2008-04-30 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
| AU2001259190B2 (en) | 2000-04-28 | 2007-01-25 | Acadia Pharmaceuticals, Inc. | Muscarinic agonists |
| US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| IL162616A0 (en) | 2001-12-28 | 2005-11-20 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US20050130961A1 (en) | 2003-03-28 | 2005-06-16 | Davis Robert E. | Muscarinic M1 receptor agonists for pain management |
-
2002
- 2002-12-23 IL IL16261602A patent/IL162616A0/xx unknown
- 2002-12-23 CA CA2470578A patent/CA2470578C/en not_active Expired - Fee Related
- 2002-12-23 WO PCT/US2002/041617 patent/WO2003057672A2/en active IP Right Grant
- 2002-12-23 MX MXPA04006281A patent/MXPA04006281A/es active IP Right Grant
- 2002-12-23 CN CNB028270495A patent/CN100402032C/zh not_active Expired - Fee Related
- 2002-12-23 DK DK02794441T patent/DK1461318T3/da active
- 2002-12-23 DE DE60206198T patent/DE60206198T2/de not_active Expired - Lifetime
- 2002-12-23 RU RU2004123203/04A patent/RU2292346C2/ru not_active IP Right Cessation
- 2002-12-23 ES ES02794441T patent/ES2251624T3/es not_active Expired - Lifetime
- 2002-12-23 AU AU2002359875A patent/AU2002359875B2/en not_active Ceased
- 2002-12-23 US US10/329,455 patent/US7307075B2/en not_active Expired - Fee Related
- 2002-12-23 JP JP2003557989A patent/JP4509565B2/ja not_active Expired - Fee Related
- 2002-12-23 EP EP02794441A patent/EP1461318B9/de not_active Expired - Lifetime
- 2002-12-23 KR KR1020047010190A patent/KR100972614B1/ko not_active IP Right Cessation
- 2002-12-23 AT AT02794441T patent/ATE304533T1/de active
- 2002-12-23 BR BR0215430-7A patent/BR0215430A/pt not_active Application Discontinuation
- 2002-12-23 NZ NZ533566A patent/NZ533566A/en not_active IP Right Cessation
-
2004
- 2004-06-17 IL IL162616A patent/IL162616A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA2004/05024A patent/ZA200405024B/en unknown
- 2004-07-15 NO NO20043013A patent/NO327522B1/no not_active IP Right Cessation
-
2005
- 2005-08-08 HK HK05106785.1A patent/HK1074573A1/xx not_active IP Right Cessation
-
2006
- 2006-05-03 US US11/417,865 patent/US7576078B2/en not_active Expired - Fee Related
- 2006-05-03 US US11/417,867 patent/US7576100B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304533T1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
| ATE466014T1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
| DE69926806D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| BR0317110A (pt) | Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos | |
| MA27933A1 (fr) | Inhibiteurs de l'activite de akt | |
| NO20013443D0 (no) | Triazolforbindelser med dopamin-D3-reseptoraktivitet | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| NO20021358D0 (no) | Alkylendiamin-substituerte heterocykler | |
| BR0014352A (pt) | Cetoenóis espirocìclicos substituìdos por trifluormetila | |
| BR0313233A (pt) | Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| EA200100992A1 (ru) | Ингибиторы фермента impdh | |
| ES2196072T3 (es) | Empleo de compuestos heterociclicos como ligandos de dopamina-d3. | |
| EA200800441A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов киназ | |
| ATE302606T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
| NO20055516L (no) | Kannabinoidreceptorligander og anvendelser derav | |
| EA200200208A1 (ru) | Синергитическая композиция | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| ATE342253T1 (de) | Azabicycloderivate als antagonisten des muscarinischen rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1461318 Country of ref document: EP |